News

Young children with cystic fibrosis (CF) have less mature gut bacterial growth over time than do their typically developing peers, according to a new U.S. study. “Our findings demonstrate that the gut microbiota of infants with CF fails to undergo typical developmental maturation, instead remaining entrenched in a transitional-like…

Among children with cystic fibrosis (CF), starting the approved oral therapy Orkambi (ivacaftor/lumacaftor) led to favorable changes in lung function and structure after one year, a real-world study shows. Improvements were seen in markers of small airway function and structural changes, including the lung clearance index (LCI), indicating…

Among cystic fibrosis (CF) patients treated with CFTR modulators in pivotal clinical trials, those who achieved lower sweat chloride levels — a standard assessment for diagnosing and monitoring CF — saw greater clinical improvements, according to a pooled analysis of trial data. Sweat chloride levels in patients also…

In cystic fibrosis (CF), certain immune cells show signs of dysfunction very early in life, according to a new study that used an animal model as well as blood samples from young children with CF. Researchers think immune cell deficiencies may influence the cycles of infection and inflammation that…

Cystic fibrosis (CF) patients saw improved lung function after one year of treatment with Kaftrio, sold as Trikafta in the U.S., a study found. The benefits were seen regardless of age, disease severity, or prior CFTR modulator treatment. “Using high-resolution data from a nationwide real-world setting, our study…

In adults with cystic fibrosis (CF), six of months treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) led to lower levels of biomarkers of inflammation, but higher blood levels of fat-like molecules considered to be cardiovascular risk factors, according to a recent study in Italy. While highly effective, the triple-combination therapy — available…

Oransi has donated air purifiers to help people with cystic fibrosis (CF) affected by smoke-filled air from the wildfires that flared up last month in Southern California, Claire’s Place Foundation said. The foundation’s financial assistance program provides CF patients and their families with one-time funds for air purifiers,…

Clarametyx Biosciences has announced an investment from Kineticos AMR Accelerator (KAMRA) Fund to support the development of CMTX-101, a non-antibiotic treatment candidate for persistent bacterial lung infections in people with cystic fibrosis (CF). This investment, which extends the company’s $33-million financing completed last year, will contribute…

Claire’s Place Foundation, a nonprofit supporting cystic fibrosis (CF) patients and their families, has launched the LA Fire Emergency Fund to help people with CF who are affected by the wildfires that have broken out this month in southern California. This temporary financial assistance program — being…

Prenatal Trikafta treatment of three fetuses with cystic fibrosis (CF) for an intestinal blockage called meconium ileus resulted in different outcomes, potentially due to treatment duration, according to a case series. One infant showed a complete resolution of meconium ileus at birth, one had persistent signs that were…